Prevention of Type 2 diabetes: fact or fiction?

Bibliography

• WILD S, ROGLIC G, GREEN A et al.: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27:1047-1053.
   PubMed Web of Science ®Google Scholar
• ALBERTI KGMM: The costs of non-insulin-dependent diabetes mellitus. Diabet. Med. (1997) 14:7-9.
   PubMed Web of Science ®Google Scholar
• DE MARCO R, LOCATELLI F, ZOPPINI G et al.: Cause-specific mortality in Type 2 diabetes. The verona diabetes study. Diabetes Care (1999) 22:756-761.
   PubMed Web of Science ®Google Scholar
• KLEIN R, KLEIN BEK, MOSS SE: Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann. Intern. Med. (1996) 124(1 Part 2):90-96.
   PubMed Web of Science ®Google Scholar
• GU K, COWIE CC, HARRIS MI: Mortality in adults with and without diabetes in a national cohort of the US population 1971 – 1993. Diabetes Care (1998) 21:1138-1145.
   PubMed Web of Science ®Google Scholar
• AMERICAN DIABETES ASSOCIATION: Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care (1998) 21:296-309.
   PubMed Web of Science ®Google Scholar
• JONSSON B: The economic impact of diabetes. Diabetes Care (1998) 21(Suppl. 3):C7-C10.
   PubMed Web of Science ®Google Scholar
• ZIMMET PZ: The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care (1995) 18:1050-1064.
   PubMed Web of Science ®Google Scholar
• KAHN SE, PORTE D Jr: Pathophysiology of Type II diabetes mellitus. In: Diabetes Mellitus. Porte D Jr, Sherwin RS (Eds), Stamford, Appleton and Lange (1996):487-512.
   Google Scholar
• LILLIOJA S, BOGARDUS C: Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab. Rev. (1988) 4:517-540.
   PubMed Web of Science ®Google Scholar
• UNWIN N, SHAW J, ZIMMET P et al.: Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet. Med. (2002) 19:708-723.
   PubMed Web of Science ®Google Scholar
• GAVIN JR III, ALBERTI KGMM, DAVIDSON MB et al.: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care (1997) 20:1183-1197.
   PubMed Web of Science ®Google Scholar
• LIAO D, SHOFER JB, BOYKO EJ et al.: Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. Diabetes Care (2001) 24:39-44.
   PubMed Web of Science ®Google Scholar
• CARNETHON MR, PALANIAPPAN LP, BURCHFIEL CM et al.: Serum insulin, obesity, and the incidence of Type 2 diabetes in black and white adults: the atherosclerosis risk in communities study: 1987 – 1998. Diabetes Care (2002) 25:1358-1364.
   PubMed Web of Science ®Google Scholar
• LIM SC, TAI ES, TAN BY et al.: Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American diabetes association diagnostic criteria and the 1998 World health organization provisional report. Diabetes Care (2000) 23:278-282.
   PubMed Web of Science ®Google Scholar
• KRISKA AM, BENNETT PH: An epidemiological perspective of the relationship between physical activity and NIDDM: from activity assessment to intervention. Diabetes Metab. Rev. (1992) 8:355-372.
   PubMed Web of Science ®Google Scholar
• PRENTICE AM, JEBB SA: Obesity in Britain: gluttony or sloth? BMJ (1995) 311:437-439.
   PubMed Web of Science ®Google Scholar
• HU FB, MANSON JE, STAMPFER MD et al.: Diet, lifestyle, and the risk of Type 2 diabetes mellitus in women. N. Engl. J. Med. (2001) 345:790-797.
   PubMed Web of Science ®Google Scholar
• ERIKSSON KF, LINDGARDE F: Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmo feasibility study. Diabetologia (1991) 34:891-898.
   PubMed Web of Science ®Google Scholar
• PAN XR, LI G-W, HU Y-H et al.: The Da Qing IGT and diabetes study. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care (1997) 20:537-544.
   PubMed Web of Science ®Google Scholar
• TUOMILEHTO J, LINDSTROM J, ERIKSSON JG et al.: Prevention of Type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. (2001) 344:1343-1350.
   PubMed Web of Science ®Google Scholar
• KNOWLER WC, BARRETT-CONNOR E, FOWLER SE et al.: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. (2002) 346:393-403.
   PubMed Web of Science ®Google Scholar
• THE DIABETES PREVENTION PROGRAM (DPP): Description of lifestyle intervention. Diabetes Care (2002) 25:2165-2171.
   PubMed Web of Science ®Google Scholar
• YANG W, LIXIANG L, JINWU Q et al.: The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin. J. Endocrinol. Metab. (2001) 17:131-136.
   Google Scholar
• KOSAKA K, NODA M, KUZUYA T: Prevention of Type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res. Clin. Pract. (2005) 67:152-162.
   PubMed Web of Science ®Google Scholar
• RAMACHANDRAN A, SNEHALATHA C, MARY S et al.: The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent Type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia (2006) 49:289-297.
   PubMed Web of Science ®Google Scholar
• KOSAKA K: Diagnostic criteria for diabetes mellitus in Japan – from a report of the Japan diabetes society (JDS) committee on the diagnosis of diabetes mellitus, 1982. Diabetes res. Clin. Pract. (1994) 24(Suppl.):S59-S62.
   Web of Science ®Google Scholar
• THE DIABETES PREVENTION PROGRAM RESEARCH GROUP: Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care (2003) 26:977-980.
   PubMed Web of Science ®Google Scholar
• CHIASSON JL, JOSSE RG, GOMIS R et al.: Acarbose for prevention of Type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 359:2072-2077.
   PubMed Web of Science ®Google Scholar
• THE EXPERT COMMITTEE ON THE DIAGNOSIS AND CLASSIFICATION OF DIABETES MELLITUS: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care (1997) 20:1183-1197.
   PubMed Web of Science ®Google Scholar
• CHIASSON JL, JOSSE RG, GOMIS R et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM trial. JAMA (2003) 290:486-494.
   PubMed Web of Science ®Google Scholar
• HANEFELD M, CHIASSON JL, KOEHLER C et al.: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke (2004) 35:1073-1078.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Preservation of pancreatic β-cell function and prevention of Type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes (2002) 51:2796-2803.
   PubMed Web of Science ®Google Scholar
• KNOWLER WC, HAMMAN RF, EDELSTEIN SL et al.: Prevention of Type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes (2005) 54:1150-1156.
   PubMed Web of Science ®Google Scholar
• TORGERSON JS, HAUPTMAN J, BOLDRIN MN et al.: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care (2004) 27:155-161.
   PubMed Web of Science ®Google Scholar
• BOSCH J, YUSUF S, GERSTEIN HC et al.: Effect of ramipril on the incidence of diabetes. N. Engl. J. Med. (2006) 355:1551-1562.
   PubMed Web of Science ®Google Scholar
• GERSTEIN HC, YUSUF S, BOSCH J et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 368:1096-1105.
   PubMed Web of Science ®Google Scholar
• DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet (2005) 366:1279-1289.
   PubMed Web of Science ®Google Scholar
• KAHN SE, HAFFNER SM, HEISE MA et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. (2006) 355:2427-2443.
   PubMed Web of Science ®Google Scholar
• GENUTH S, ALBERTI KG, BENNETT P et al.: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care (2003) 26:3160-3167.
   PubMed Web of Science ®Google Scholar
• BALKAU B, HU G, QIAO Q et al.: Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE study. Diabetologia (2004) 47:2118-2128.
   PubMed Web of Science ®Google Scholar
• The Diabetes Prevention Program Research Group: Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of Type 2 diabetes. Diabetes Care (2003) 26:2518-2523.
   PubMed Web of Science ®Google Scholar
• CARO JJ, GETSIOS D, CARO I et al.: Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada. Diabet. Med. (2004) 21:1229-1236.
   PubMed Web of Science ®Google Scholar
• JOSSE RG, MCGUIRE AJ, SAAL GB: A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int. J. Clin. Pract. (2006) 60:847-855.
   PubMed Web of Science ®Google Scholar
• PALMER AJ, ROZE S, VALENTINE WJ et al.: Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom. Clin. Ther. (2004) 26:304-321.
   PubMed Web of Science ®Google Scholar
• KLONOFF DC, SCHWARTZ DM: An economic analysis of interventions for diabetes. Diabetes Care (2000) 23:390-404.
   PubMed Web of Science ®Google Scholar
• EVERS T, LUDDEKE HJ, LIEBL A et al.: Economic value of acarbose treatment in persons with impaired glucose tolerance (IGT) for the German health care system. Value Health (2004) 7:741.
   Web of Science ®Google Scholar
• QUILICI S, CHANCELLOR J, MACLAINE G et al.: Cost-effectiveness of acarbose for the management of impaired glucose tolerance in Sweden. Int. J. Clin. Pract. (2005) 59:1143-1152.
   PubMed Web of Science ®Google Scholar
• UR E, CAPES SE, HANNA A et al.: Screening and prevention. Can. J. Diabetes (2003) 27(Suppl. 2):S10-S13.
   Google Scholar
• COLAGIURI S, HUSSAIN Z, ZIMMET P et al.: Screening for Type 2 diabetes and impaired glucose metabolism: the Australian experience. Diabetes Care (2004) 27:367-371.
   PubMed Web of Science ®Google Scholar
• ZHANG P, ENGELGAU MM, VALDEZ R et al.: Efficient cutoff points for three screening tests for detecting undiagnosed diabetes and pre-diabetes: an economic analysis. Diabetes Care (2005) 28:1321-1325.
   PubMed Web of Science ®Google Scholar
• VAN DE LAAR FA, LUCASSEN PL, AKKERMANS RP et al.: α-Glucosidase inhibitors for patients with Type 2 diabetes: results from a cochrane systematic review and meta-analysis. Diabetes Care (2005) 28:154-163.
   PubMed Web of Science ®Google Scholar
• KOUSTA E, LAWRENCE NJ, PENNY A et al.: Implications of new diagnostic criteria for abnormal glucose homeostasis in women with previous gestational diabetes. Diabetes Care (1999) 22:933-937.
   PubMed Web of Science ®Google Scholar
• LARSSON H, LINDGARDE F, BERGLUND G et al.: Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia (2000) 43:1224-1228.
   PubMed Web of Science ®Google Scholar
• SIMMONS D, THOMPSON CF, ENGELGAU MM: Controlling the diabetes epidemic: how should we screen for undiagnosed diabetes and dysglycaemia? Diabet. Med. (2005) 22:207-212.
   PubMed Web of Science ®Google Scholar
• ZHANG P, ENGELGAU MM, VALDEZ R et al.: Costs of screening for pre-diabetes among US adults: a comparison of different screening strategies. Diabetes Care (2003) 26:2536-2542.
   PubMed Web of Science ®Google Scholar
• LINDSTROM J, TUOMILEHTO J: The diabetes risk score: a practical tool to predict Type 2 diabetes risk. Diabetes Care (2003) 26:725-731.
   PubMed Web of Science ®Google Scholar
• BAUMAN AE: Updating the evidence that physical activity is good for health: an epidemiological review, 2000 – 2003. J. Sci. Med. Sport (2004) 7:6-19.
   PubMedGoogle Scholar
• GORAN MI, BALL GD, CRUZ ML: Obesity and risk of Type 2 diabetes and cardiovascular disease in children and adolescents. J. Clin. Endocrinol. Metab. (2003) 88:1417-1427.
   PubMed Web of Science ®Google Scholar
• SAAD MF, KNOWLER WC, PETTITT DJ et al.: The natural history of impaired glucose tolerance in the Pima Indians. N. Engl. J. Med. (1988) 319:1500-1506.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet (1998) 352:854-865.
   PubMed Web of Science ®Google Scholar
• HANEFELD M, CAGATAY M, PETROWITSCH T et al.: Acarbose reduces the risk for myocardial infarction in Type 2 diabetic patients: meta-analysis of seven long-term studies. Eur. Heart J. (2004) 25:10-16.
   PubMed Web of Science ®Google Scholar
• RABASA-LHORET R, CHIASSON J-L: α-Glucosidase inhibitors. In: International Textbook of Diabetes Mellitus (3rd Edition). DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Eds), John Wiley & Sons Ltd, Chichester (2004):901-914.
   Google Scholar